Transverse Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Transverse Medical is a private, pre-revenue medical device company founded in 2018, headquartered in San Carlos, California. The company is developing the POINT-GUARD™ device, a cerebral embolic protection system aimed at preventing stroke and silent brain injury during transcatheter aortic valve replacement (TAVR) and other structural heart procedures. Led by co-founder and CEO Eric Goslau, the company is addressing a significant unmet clinical need where periprocedural stroke rates remain a major concern. Its technology is designed to offer comprehensive brain coverage, potentially improving patient outcomes and reducing healthcare costs associated with stroke complications.

CardiovascularNeurology

Technology Platform

The POINT-GUARD™ Cerebral Embolic Protection device, a medical device platform designed for full-brain protection by filtering embolic debris released during cardiovascular procedures like TAVR.

Opportunities

The rapid global expansion of TAVR procedures creates a large and growing addressable market for stroke prevention devices.

Increasing clinical awareness of 'silent strokes' and neurocognitive decline post-procedure expands the potential patient base and value proposition beyond just preventing major overt stroke.

Demonstrating superior full-brain protection could allow Transverse Medical to capture significant market share from first-generation, partial-protection devices.

Risk Factors

The company faces significant clinical and regulatory risk, as it must prove the safety and efficacy of its novel device in human trials to gain FDA approval.

It also faces intense competition from established, commercially available embolic protection devices and must demonstrate a clear clinical advantage to drive adoption.

As a pre-revenue startup, it carries execution and financing risk, requiring continued capital infusion to reach commercialization.

Competitive Landscape

The cerebral embolic protection market for TAVR is currently served by first-generation devices, most notably the Sentinel Cerebral Protection System (Boston Scientific), which is FDA-approved and captures debris from two of the three major cerebral vessels. Other competitors may include devices in development or approved in other regions. Transverse Medical's key differentiator is its claim of providing 'full-brain' or more comprehensive coverage, aiming to address the limitation of partial protection.

More companies in Neuroscience & CNS →More companies in United States →